These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19109035)

  • 41. Refractory Takayasu arteritis successfully treated with infliximab.
    Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
    Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.
    Song IH; Appel H; Haibel H; Loddenkemper C; Braun J; Sieper J; Rudwaleit M
    J Rheumatol; 2008 Mar; 35(3):532-6. PubMed ID: 18203308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TNF-mediated inflammatory disease.
    Bradley JR
    J Pathol; 2008 Jan; 214(2):149-60. PubMed ID: 18161752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
    Herman S; Krönke G; Schett G
    Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease].
    Hinojosa J
    Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280
    [No Abstract]   [Full Text] [Related]  

  • 46. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
    Kast RE; Altschuler EL
    J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327
    [No Abstract]   [Full Text] [Related]  

  • 47. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
    Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
    J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
    Hollander D
    Am J Gastroenterol; 2002 Aug; 97(8):1867-8. PubMed ID: 12190145
    [No Abstract]   [Full Text] [Related]  

  • 50. Infliximab and the TNF-alpha system.
    Ebert EC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G612-20. PubMed ID: 19136378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Demyelination and other neurological adverse events after anti-TNF therapy.
    Kaltsonoudis E; Voulgari PV; Konitsiotis S; Drosos AA
    Autoimmun Rev; 2014 Jan; 13(1):54-8. PubMed ID: 24035809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Remicade: six years of experience in immune-mediated inflammatory disorders].
    Guillevin L
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S5-7. PubMed ID: 16967602
    [No Abstract]   [Full Text] [Related]  

  • 53. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.
    Arend SM; Leyten EM; Franken WP; Huisman EM; van Dissel JT
    Clin Infect Dis; 2007 Dec; 45(11):1470-5. PubMed ID: 17990230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.
    Taylor PC; Williams RO; Feldmann M
    Curr Opin Biotechnol; 2004 Dec; 15(6):557-63. PubMed ID: 15560982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biologic therapies: lessons from multiple sclerosis.
    Ghosh S
    Dig Dis; 2012; 30(4):383-6. PubMed ID: 22796801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nephrotic syndrome associated with anti-tumor necrosis factor alpha therapy in a patient with rheumatoid arthritis: comment on the article by Charles et al.
    den Broeder AA; Assmann KJ; van Riel PL; Wetzels JF
    Arthritis Rheum; 2002 Jun; 46(6):1691-3; author reply 1693. PubMed ID: 12115204
    [No Abstract]   [Full Text] [Related]  

  • 57. Demyelination and inhibition of tumor necrosis factor (TNF).
    Magnano MD; Robinson WH; Genovese MC
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S134-40. PubMed ID: 15552527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation.
    Nieder C; Schnaiter A; Weber WA; Schill S; Andratschke N; Schwaiger M; Molls M
    Anticancer Res; 2007; 27(4B):2353-7. PubMed ID: 17695525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.
    Borhani Haghighi A; Safari A
    Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588
    [No Abstract]   [Full Text] [Related]  

  • 60. Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies.
    Davis SA; Johnson RR; Pendleton JW
    J Rheumatol; 2008 Jul; 35(7):1469-70. PubMed ID: 18609727
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.